InvestSMART

Integral Diagnostics Limited (ASX:IDX)

ALERT: Price-sensitive ASX Announcement for IDX
Current share price for IDX : $2.310 0.13 (5.96%)+
Announcement
Release
10 Aug 2026 9:05AM
Price at Release
$2.180
Full Release
download
Summary
Integral Diagnostics Limited (IDX) reported preliminary financial results for FY26, with significant growth in revenue, expected to reach between $788m and $790m. The company anticipates a 50% increase in operating NPAT to $47m-$48m, and a 23% rise in diluted Operating EPS to 12.5cps-12.7cps. The debt ratio improved, while capital expenditure was in line with expectations. IDX also announced the appointment of Jenny Martin as the new Chief Financial Officer effective October 5, 2026, succeeding Craig White, who will retire after a successful transition period.
Key Points
  • Integral Diagnostics Limited (IDX) announced preliminary financial results for FY26.
  • Revenue is expected to be approximately $788m to $790m, a 25% increase from FY25.
  • Operating EBITDA is anticipated to be around $164m to $165m, up 30% from the previous year.
  • The operating EBITDA margin is projected to be approximately 20.8% to 21.0%.
  • Operating NPAT is estimated to be between $47m and $48m, representing a 50% increase.
  • Diluted Operating EPS is expected to be approximately 12.5cps to 12.7cps.
  • Debt to Operating EBITDA ratio improved to an estimated 2.3x at the end of FY26.
  • Capital expenditure for growth and replacement was about $50m, aligning with guidance.
  • IDX appointed Jenny Martin as the new Chief Financial Officer, effective October 5, 2026.
  • Jenny Martin has extensive experience in healthcare technology and finance.
  • Current CFO Craig White will retire after 4½ years, following a transition period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.